CSIMarket
 
Natera inc   (NTRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $89.5200 $1.81 2.064%
Day's High: $89.975 Week Perf: 0.27 %
Day's Low: $ 87.35 30 Day Perf: 28.49 %
Volume (M): 2,078 52 Wk High: $ 93.48
Volume (M$): $ 186,014 52 Wk Avg: $55.39
Open: $87.44 52 Wk Low: $36.90



 Market Capitalization (Millions $) 10,297
 Shares Outstanding (Millions) 115
 Employees 2,800
 Revenues (TTM) (Millions $) 1,083
 Net Income (TTM) (Millions $) -435
 Cash Flow (TTM) (Millions $) 176
 Capital Exp. (TTM) (Millions $) 39

Natera Inc
Natera Inc is a multinational healthcare company that specializes in genetic testing and diagnostic solutions. Founded in 2003, the company is headquartered in San Carlos, California, but has operations across the United States, Europe, and Asia. Natera is publicly traded on the NASDAQ and currently employs over 1,200 people worldwide. The company's mission is to improve the lives of millions of patients and families by providing them with advanced genetic testing and diagnostics.

Natera offers a range of genetic testing solutions that enable healthcare providers to diagnose, monitor, and manage various health conditions. The company specializes in non-invasive prenatal testing (NIPT), which uses cell-free DNA (cfDNA) technology to detect certain genetic abnormalities in the fetus without the need for invasive procedures. The company's flagship product, Panorama, is a market-leading NIPT test that screens for common chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome.

In addition to NIPT, Natera provides a range of other genetic testing solutions for reproductive health, oncology, and organ transplantation. The company's products include tests for hereditary cancer risk assessment, inherited cardiovascular conditions, and reproductive genetics. Natera also offers a liquid biopsy test, Signatera, that detects the presence of circulating tumor DNA in cancer patients, providing insight into disease progression and treatment efficacy.

Beyond its focus on genetic testing and diagnostics, Natera is also engaged in research and development activities aimed at advancing the field of genomics. The company has partnerships with leading academic and research institutions and invests heavily in innovation and technology development. Natera has a portfolio of more than 300 issued and pending patents and has won numerous awards for its pioneering work in genomics.

In recent years, Natera has experienced significant growth, driven by rising demand for genetic testing and a growing trend towards personalized medicine. The company's financial performance has been strong, with revenues of $355.6 million in 2020, up from $302.3 million in 2019. Natera is committed to continued growth and expansion across its key markets, with a focus on advancing its technology, expanding its product offerings, and increasing market share.


   Company Address: 13011 McCallen Pass Austin 78753 TX
   Company Phone Number: 980-9190   Stock Exchange / Ticker: NASDAQ NTRA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Natera Collaborates on Innovative Clinical Trial to Uphold Treatment for Stage II Colorectal Cancer

Published Mon, Mar 18 2024 11:00 AM UTC

Natera, a leading pioneer in cell-free DNA testing, has joined forces with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne for the groundbreaking CIRCULATE-PRODIGE-70 study. This phase III clinical trial, conducted in France, aims to evaluate the potential benefits of Signatera, Natera's innovative molecular residual disease (MRD)-guided adjuvant...

Product Service News

New Clinical Guideline Supports Genetic Testing as a Vital Tool for Diagnosing Chronic Kidney Disease

Published Thu, Mar 14 2024 12:00 PM UTC

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseA recent publication by the Kidney Disease Improving Global Outcomes (KDIGO) organization has introduced a updated clinical practice guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). The guideline, slated for implementation in 2024, recommends...

Product Service News

Natera to Unveil Promising Advances in Cancer Detection at the 2024 Society of Gynecologic Oncology Annual Meeting

Published Tue, Mar 12 2024 12:00 PM UTC

Natera, a leading company specializing in cell-free DNA testing, has recently announced the presentation of new data on its innovative molecular residual disease (MRD) test, Signatera, and hereditary cancer test, Empower. This groundbreaking research will be showcased at the upcoming 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, scheduled from...

Product Service News

Natera Secures Commercial Coverage for Prospera Heart and Prospera Kidney Tests from Leading BCBS Plan, Evolving Transplant Medicine

Published Thu, Mar 7 2024 1:00 PM UTC

Natera, a leading company in cell-free DNA testing, has announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS) plans in the United States. This development is significant as it will greatly benefit transplant recipients and providers by allowing them access to advance...

Natera Inc

Natera Inc Sees Strong Growth in Shares and Financial Performance in Recent Fiscal Period

Natera Inc, a global leader in cell-free DNA testing, has recently recorded a solid gain of 5.37% in its shares during the past five trading days. This increase brings the share price to a high of 19.82% during the first quarter of 2024. Additionally, Natera Inc shares have reached their 52-week high.
In terms of financial performance, Natera Inc has shown significant improvement. In the most recent fiscal period, the company reported a decrease in loss per share to $-0.57, compared to $-1.31 a year prior. The earnings per share (EPS) also improved from $-0.95 in the previous reporting season. Furthermore, the revenue jumped by 43.2% to $311.11 million from $217.25 million in the same reporting season a year ago. Sequentially, the revenue improved by 15.952% from $268.31 million.






 

Natera Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Natera Inc does not provide revenue guidance.

Earnings Outlook
Natera inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com